453 related articles for article (PubMed ID: 16318413)
1. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
[TBL] [Abstract][Full Text] [Related]
3. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
4. Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore.
Paton NI; Chapman CA; Sangeetha S; Mandalia S; Bellamy R; Beck EJ
Int J STD AIDS; 2006 Oct; 17(10):699-705. PubMed ID: 17059641
[TBL] [Abstract][Full Text] [Related]
5. Estimating the cost to rural ambulating HIV/AIDS patients on highly active antiretroviral therapy (HAART) in rural Ghana: a pilot study.
Apanga S; Punguyire D; Adjei G
Pan Afr Med J; 2012; 12():21. PubMed ID: 22826745
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
[TBL] [Abstract][Full Text] [Related]
7. The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.
Beck EJ; Tolley K; Power A; Mandalia S; Rutter P; Izumi J; Beecham J; Gray A; Barlow D; Easterbrook P; Fisher M; Innes J; Kinghorn G; Mandel B; Pozniak A; Tang A; Tomlinson D; Williams I
Pharmacoeconomics; 1998 Dec; 14(6):639-52. PubMed ID: 10346416
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
9. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
[TBL] [Abstract][Full Text] [Related]
10. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
[TBL] [Abstract][Full Text] [Related]
11. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy.
de Cherif TK; Schoeman JH; Cleary S; Meintjes GA; Rebe K; Maartens G
BMC Infect Dis; 2009 Dec; 9():205. PubMed ID: 20003472
[TBL] [Abstract][Full Text] [Related]
12. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
[TBL] [Abstract][Full Text] [Related]
13. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.
Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD;
Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308
[TBL] [Abstract][Full Text] [Related]
14. The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients.
Harling G; Wood R
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):348-54. PubMed ID: 17496562
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
18. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G
Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan.
Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Chen MY; Huang LY; Hwang JS; Wang JD
J Formos Med Assoc; 2007 Aug; 106(8):631-40. PubMed ID: 17711796
[TBL] [Abstract][Full Text] [Related]
20. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia.
Tagar E; Sundaram M; Condliffe K; Matatiyo B; Chimbwandira F; Chilima B; Mwanamanga R; Moyo C; Chitah BM; Nyemazi JP; Assefa Y; Pillay Y; Mayer S; Shear L; Dain M; Hurley R; Kumar R; McCarthy T; Batra P; Gwinnell D; Diamond S; Over M
PLoS One; 2014; 9(11):e108304. PubMed ID: 25389777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
